Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC With Acquired Resistance to First or Third Generation EGFR TKIs
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2018
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Necitumumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.
- 26 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.